While Bristol Myers Squibb anxiously awaits an FDA decision on its TYK2 inhibitor to treat plaque psoriasis, the pharma is hoping some proof of concept data could help the med find another home ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, ...
Nimbus Therapeutics said Monday that it raised $125 million in private financing to test its experimental therapies in autoimmune diseases and cancer. The Cambridge biotech’s most advanced program is ...
In autoimmune diseases, Idera is developing inhibitors of TLRs 7, 8, and 9 for the potential treatment of psoriasis, lupus, and other diseases. Idera’s lead clinical candidate is IMO-3100, an ...
Increased odds of atherosclerotic cardiovascular disease seen in association with cutaneous lupus and systemic lupus, but not psoriasis. HealthDay News — Cutaneous lupus erythematosus (CLE) is ...
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...
Please provide your email address to receive an email when new articles are posted on . Patients with cutaneous lupus were 1.72 times more likely to have cardiovascular disease than matched controls.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback